List of Excipients in Branded Drug QMIIZ ODT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TerSera Therapeutics LLC	QMIIZ ODT	meloxicam	70720-175	ANHYDROUS CITRIC ACID
TerSera Therapeutics LLC	QMIIZ ODT	meloxicam	70720-175	ASPARTAME
TerSera Therapeutics LLC	QMIIZ ODT	meloxicam	70720-175	GELATIN
TerSera Therapeutics LLC	QMIIZ ODT	meloxicam	70720-175	MANNITOL

QMIIZ ODT Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

QMIIZ ODT is a differentiated meloxicam product that uses an orally disintegrating tablet platform to create administration and convenience advantages over conventional meloxicam tablets and capsules. Its commercial value rests less on the active ingredient, which is generic and widely available, and more on rapid disintegration, taste management, dose flexibility, portability, and formulation know-how.

The product contains meloxicam in 7.5 mg and 15 mg strengths and is approved for relief of osteoarthritis and rheumatoid arthritis symptoms in adults. QMIIZ ODT was developed by Zydus Lifesciences and received FDA approval in April 2020. The product is not a biologic, so biosimilar substitution is not relevant. The principal competitive risks are conventional meloxicam generics, alternative NSAIDs, authorized-generic strategies, and potential replication of the orally disintegrating formulation.

What is QMIIZ ODT and how does its formulation differ from standard meloxicam?

QMIIZ ODT is an orally disintegrating tablet containing meloxicam. The dosage form is designed to disintegrate in the mouth without requiring the patient to swallow a conventional tablet with water.

The FDA labeling identifies the following inactive ingredients:

Excipient	Probable formulation function
Mannitol	Bulking agent, diluent, mouthfeel modifier and cooling sweetener
Microcrystalline cellulose	Structural diluent and compression aid
Crospovidone	Superdisintegrant that promotes rapid tablet breakup
Colloidal silicon dioxide	Glidant and powder-flow aid
Magnesium stearate	Lubricant
Sucralose	High-intensity sweetener
Strawberry flavor	Taste masking and patient acceptability

Source: FDA-approved QMIIZ ODT prescribing information and DailyMed product labeling.[1,2]

The excipient system reflects the standard technical requirements for an oral disintegrating product:

1. The tablet must have sufficient mechanical strength for packaging and handling.
2. It must disintegrate rapidly in saliva.
3. It must reduce the bitter or irritating taste associated with meloxicam.
4. It must provide acceptable mouthfeel without excessive grittiness.
5. It must remain stable under normal storage and distribution conditions.

The formulation does not depend on a complex delivery device, lipid vehicle, coating system or modified-release mechanism. That lowers manufacturing complexity but also limits the protection available from formulation complexity.

How does the QMIIZ ODT excipient strategy create commercial value?

The principal value is patient administration convenience.

Meloxicam is commonly used by patients with chronic osteoarthritis and rheumatoid arthritis. These populations can include older adults, patients with dysphagia, and patients who have difficulty taking tablets during travel or outside the home. An orally disintegrating dosage form can address those use cases without changing the active ingredient or its approved therapeutic indication.

Mannitol provides more than tablet bulk

Mannitol is particularly suitable for orally disintegrating tablets because it has good mouthfeel, relatively low hygroscopicity and a cooling sensation during dissolution. Those attributes can improve patient acceptance compared with less soluble or more hygroscopic diluents.

For QMIIZ ODT, mannitol likely supports:

• Rapid dissolution in saliva
• A less chalky mouthfeel
• Reduced moisture sensitivity compared with some alternative polyols
• Tablet mass and compressibility
• A sweet or cooling sensory profile that supports taste masking

Mannitol can increase formulation cost compared with conventional lactose or dibasic calcium phosphate systems. That cost is commercially acceptable when the product commands a dosage-form premium.

Crospovidone supports rapid disintegration

Crospovidone is the primary functional excipient for rapid tablet breakup. It absorbs liquid through capillary action and promotes disintegration without forming a highly viscous gel.

For an ODT product, crospovidone selection and loading can affect:

• Disintegration time
• Tablet friability
• Compression force
• Dissolution performance
• Mouthfeel
• Manufacturing throughput

A higher crospovidone level may accelerate disintegration but can reduce tablet strength or increase production cost. The commercial formulation challenge is to achieve a short disintegration time without creating a fragile tablet.

Sucralose and strawberry flavor address taste risk

Meloxicam has an unpleasant taste profile that can become more important when the tablet dissolves directly in the mouth. Conventional tablets reduce direct taste exposure because they are swallowed intact. An ODT removes that barrier.

Sucralose and strawberry flavor therefore have a commercial function, not merely an aesthetic one. They support:

• Patient willingness to retain the tablet in the mouth
• Reduced refusal among patients sensitive to bitterness
• Better adherence in chronic treatment
• Product differentiation from unflavored meloxicam tablets

Taste masking is also a potential source of formulation know-how. A generic developer may reproduce the active ingredient and broad excipient categories but still encounter problems with aftertaste, flavor persistence, sensory balance and batch-to-batch consistency.

What formulation patents and intellectual-property barriers protect QMIIZ ODT?

The active ingredient, meloxicam, is an established NSAID and is no longer protected by basic compound patent exclusivity. The potentially valuable IP relates to the dosage form, excipient ratios, manufacturing process, taste masking, tablet performance and method of administration.

Potentially protectable formulation elements include:

• Specific meloxicam particle-size distributions
• Defined mannitol and crospovidone ratios
• Compression parameters
• Granulation or direct-compression conditions
• Disintegration-time specifications
• Dissolution profiles
• Taste-masking combinations
• Moisture-control packaging
• Tablet hardness and friability ranges
• Flavor and sweetener systems
• Stability performance under accelerated conditions

The practical strength of such claims depends on their breadth and enforceability. A patent limited to a narrow excipient ratio may be designed around by changing the grade or amount of mannitol, substituting a different superdisintegrant, or modifying the flavor system. A patent that combines composition, performance and manufacturing limitations can create a stronger barrier but may be harder to prove in litigation.

What is the Orange Book status of QMIIZ ODT?

QMIIZ ODT was approved under an FDA new drug application rather than as an abbreviated new drug application. The product’s FDA approval provided regulatory exclusivity associated with the approved formulation and supporting clinical investigations. The relevant three-year exclusivity period began with the April 2020 approval and would have ended in approximately April 2023, assuming the standard three-year exclusivity framework and no separate extension.[3]

Patent protection must be assessed through the FDA Orange Book listing for the applicable NDA. Orange Book-listed patents can create Paragraph IV certification risks for an ANDA applicant. The key commercial question is whether a challenger can certify that the listed patent is invalid, unenforceable or not infringed, or whether it must wait for patent expiration.

Patent scope is especially important for QMIIZ ODT because a conventional meloxicam ANDA does not necessarily compete directly with the ODT product on a dosage-form basis. An ANDA applicant seeking an ODT version would face formulation-development and patent risks that do not apply to a standard meloxicam tablet.

When did QMIIZ ODT lose regulatory exclusivity?

QMIIZ ODT received FDA approval in 2020. The standard three-year exclusivity period associated with a new formulation supported by new clinical investigations would have expired in 2023.[1,3]

Regulatory exclusivity and patent exclusivity are separate:

Protection type	Relevance to QMIIZ ODT
New chemical entity exclusivity	Not applicable because meloxicam is an established active ingredient
Three-year exclusivity	Relevant to the approved new dosage form and supporting clinical work
Five-year NCE exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable based on the approved indication
Patent protection	Depends on the patents listed for the NDA and any additional enforceable formulation rights
Pediatric exclusivity	Applies only if separately awarded by FDA

After regulatory exclusivity ends, a competitor may pursue an ANDA or another FDA pathway, subject to any applicable listed patents and formulation-specific requirements.

Which companies are challenging QMIIZ ODT?

The principal competitive threat is not a biosimilar. It is a generic or alternative meloxicam product.

Potential competitor categories include:

• Conventional meloxicam tablet manufacturers
• Meloxicam capsule manufacturers
• Meloxicam oral suspension developers
• Companies developing their own meloxicam ODT
• Contract manufacturers supplying private-label products
• Branded NSAID competitors, including celecoxib, diclofenac and naproxen products

A standard meloxicam generic may compete on price but does not fully replicate the QMIIZ ODT administration experience. A competing ODT would pose a more direct threat and could use a different excipient architecture, such as:

• Mannitol with crospovidone
• Lactose or isomalt-based systems
• Co-processed excipients
• Effervescent disintegration
• Spray-dried taste-masked meloxicam
• Sublingual or buccal delivery approaches

The commercial success of a competing ODT would depend on bioequivalence, taste, tablet robustness, packaging, supply reliability and payer coverage.

How strong is the QMIIZ ODT patent estate?

The patent estate is likely stronger as a formulation and know-how package than as a basic active-ingredient estate.

Strengths

• ODT performance can be tied to measurable dissolution and disintegration outcomes.
• Taste masking can create practical development barriers.
• Manufacturing conditions may be difficult to reproduce without access to development know-how.
• A competitor must balance tablet strength, rapid disintegration and acceptable mouthfeel.
• Packaging requirements can increase the cost and complexity of generic replication.

Weaknesses

• The excipients are widely used in the pharmaceutical industry.
• Mannitol, crospovidone, sucralose and flavor systems are generally available from multiple suppliers.
• A competitor may design around narrow composition claims.
• Meloxicam is a mature, low-cost active ingredient.
• Clinical differentiation is limited because the therapeutic indication is already well established.

The strongest barriers are likely to be the combination of formulation parameters, manufacturing controls and sensory performance rather than any individual excipient.

What manufacturing and supply-chain barriers affect QMIIZ ODT?

ODT production requires tighter process control than many conventional immediate-release tablets.

Important manufacturing variables include:

• Particle-size distribution of meloxicam and excipients
• Blend uniformity at low drug loading
• Lubrication time and magnesium stearate distribution
• Compression force
• Tablet hardness
• Friability
• Disintegration time
• Environmental humidity
• Flavor homogeneity
• Packaging moisture protection

The 7.5 mg strength presents a blend-uniformity challenge because the drug represents a relatively small proportion of the tablet mass. The 15 mg strength may provide a wider process window but can create different taste and dissolution behavior.

Moisture control is commercially important. ODTs can be more sensitive to mechanical damage and humidity than conventional compressed tablets. Unit-dose blister packaging can protect product quality but increases packaging cost. Bottles may reduce cost but require stronger moisture-barrier systems and desiccant management.

What commercial opportunities exist for QMIIZ ODT?

Premium convenience positioning

QMIIZ ODT can support a price premium over standard meloxicam tablets if prescribers and payers recognize value in water-free administration. The most commercially receptive segments are likely to include:

• Older adults with swallowing difficulty
• Patients with chronic arthritis
• Caregivers administering medication outside clinical settings
• Patients who travel or work away from home
• Patients with poor adherence to conventional tablets
• Pharmacies and telehealth providers seeking differentiated dosage forms

Line extensions

The platform could support additional products, subject to FDA requirements:

• Alternative flavor systems
• Lower-dose strengths
• Unit-dose travel packaging
• Combination products
• Pediatric or adolescent formulations if clinically justified
• Other NSAIDs using the same ODT manufacturing platform

A lower-dose product could target patients requiring dose titration or those at higher NSAID-related risk. Combination products would face more complex regulatory, clinical and intellectual-property requirements.

Licensing and contract development

The formulation platform has potential value for:

• Licensing to regional pharmaceutical companies
• Private-label ODT products
• Contract development and manufacturing
• Co-development of other poorly palatable small molecules
• Technology transfer for orally disintegrating analgesics

The most valuable licensing proposition would be the manufacturing process and performance package, not access to commodity excipients. A partner would pay for reproducible scale-up, stability data, taste-masking expertise and regulatory documentation.

Geographic expansion

The ODT format can be attractive in markets where:

• Older populations are growing
• Water-free dosing is commercially valued
• Pharmacy dispensing is fragmented
• Branded generics command premiums
• Local competitors have limited ODT capability

The main geographic barriers are local regulatory requirements, trademark clearance, excipient acceptability, flavor preferences, packaging costs and national reimbursement policies.

How does QMIIZ ODT compare with conventional meloxicam generics?

Factor	QMIIZ ODT	Conventional meloxicam generic
Active ingredient	Meloxicam	Meloxicam
Administration	Disintegrates in the mouth	Swallowed with water
Patient convenience	Higher for dysphagia and travel use	Standard
Manufacturing complexity	Moderate to high	Lower
Excipient differentiation	Material	Usually limited
Taste-masking requirement	High	Low
Packaging needs	Often higher	Standard bottle or blister
Price competition	Can support a premium	Usually intense
Generic substitution	Depends on dosage-form and regulatory status	Broad conventional-generic competition
Biosimilar risk	None	None

QMIIZ ODT’s differentiation is therefore dosage-form based. It does not create a new pharmacologic mechanism or a new meloxicam indication.

What generic launch scenarios exist for QMIIZ ODT?

Scenario 1: Conventional meloxicam generics continue to dominate volume

This is the most likely baseline. Conventional meloxicam products have lower manufacturing and packaging costs and are well established in formularies.

Scenario 2: An ODT generic enters after patent clearance

A direct ODT challenger could reduce pricing power and force greater payer discounting. The challenger would need to demonstrate bioequivalence and meet ODT quality expectations.

Scenario 3: A non-infringing ODT design launches

A competitor may avoid key formulation claims by changing the superdisintegrant, diluent, flavor, compression process or moisture-control approach. This scenario would reduce the value of narrow formulation patents.

Scenario 4: QMIIZ ODT retains a niche premium

The product may preserve commercial value if patients, caregivers or prescribers prioritize administration convenience and if reimbursement does not force substitution to the lowest-cost meloxicam product.

What revenue exposure does QMIIZ ODT face?

Revenue exposure is driven by dosage-form substitution rather than loss of the entire meloxicam market.

The most sensitive variables are:

• Net price relative to standard meloxicam
• Payer tier placement
• Pharmacy substitution rules
• Number of direct ODT competitors
• Patient persistence and refill rates
• Prescriber awareness
• Cost of blister packaging
• Supply continuity
• Patent litigation outcomes

A conventional meloxicam generic can erode the overall branded NSAID price environment without fully replacing QMIIZ ODT. A therapeutically equivalent ODT competitor would pose a greater risk because it would target the product’s primary differentiation.

What patent litigation and Paragraph IV risks affect QMIIZ ODT?

An ANDA applicant that seeks approval before expiration of an Orange Book-listed patent may submit a Paragraph IV certification. The NDA holder could then bring an infringement action within the statutory window, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[4]

The central litigation issues would likely include:

• Whether the ANDA formulation falls within the asserted claims
• Whether the claims are obvious in view of known ODT excipient systems
• Whether the patent adequately describes and enables the claimed formulation
• Whether the patent claims a measurable performance outcome
• Whether the accused process uses the claimed manufacturing steps
• Whether the listed patent is properly Orange Book eligible

Settlement agreements could include a delayed generic launch, a license for an authorized generic, supply arrangements or a royalty-bearing formulation license. No settlement should be assumed without a documented court filing, FDA notice or company disclosure.

Key Takeaways

• QMIIZ ODT is a meloxicam orally disintegrating tablet available in 7.5 mg and 15 mg strengths.
• Its principal excipients are mannitol, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose and strawberry flavor.
• Mannitol, crospovidone and taste-masking excipients are central to the product’s commercial differentiation.
• The active ingredient is mature and commoditized; formulation, manufacturing and sensory performance provide the main value.
• Three-year FDA formulation exclusivity would have ended around April 2023.
• Biosimilar risk is irrelevant because QMIIZ ODT is a small-molecule drug.
• The strongest direct threat is a competing meloxicam ODT, not a conventional meloxicam tablet alone.
• Commercial opportunities include premium branded-generic positioning, regional licensing, private-label supply and expansion of the ODT platform.
• Patent strength depends on claim breadth, formulation-performance limitations and manufacturing know-how.
• Generic entry risk is highest if a challenger can reproduce rapid disintegration and acceptable taste while designing around narrow composition claims.

FAQs

Does QMIIZ ODT contain lactose?

The FDA-listed inactive ingredients identify mannitol rather than lactose as the principal bulking excipient.[1,2]

Is QMIIZ ODT suitable for patients who cannot swallow tablets?

Its orally disintegrating format is designed to reduce the need to swallow an intact tablet with water. It remains an oral meloxicam product and carries the standard NSAID warnings and contraindications in its FDA labeling.

Can a generic manufacturer copy the QMIIZ ODT excipients?

A generic manufacturer may use the same excipients if the formulation does not infringe enforceable patent claims and meets FDA requirements. The practical challenge is reproducing the product’s performance, taste and stability.

Does QMIIZ ODT have a different mechanism of action from meloxicam tablets?

No. QMIIZ ODT contains meloxicam, a preferential cyclooxygenase-2 inhibitor within the NSAID class. The primary difference is dosage form and administration.

What is the main investment risk associated with QMIIZ ODT?

The main risk is limited willingness among payers and patients to pay a premium for convenience when low-cost conventional meloxicam products are widely available. Direct ODT competition would increase that pressure.

References

1. U.S. Food and Drug Administration. (2020). QMIIZ ODT (meloxicam) orally disintegrating tablets: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: QMIIZ ODT- meloxicam tablet.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2023). Hatch-Waxman Amendments and abbreviated new drug applications.